JointHealth™ express   January 16, 2013

Reminder: Do you have juvenile idiopathic arthritis or care for someone who does? We want your valuable input

Last week, Arthritis Consumer Experts (ACE) sent out a JointHealth™ express announcing that we are gathering patient input to submit to the Common Drug Review (CDR).

If you have not yet had a chance to get involved, there is still time. The CDR continues to accept input on the manufacturer’s submission for adalimumab (Humira®) for the treatment of juvenile idiopathic arthritis (JIA).

So, if you live with JIA, or care for someone with the disease, and you would like to provide your input, please contact us by Thursday, January 17. This will allow us enough time to include your submission and meet the deadline, which is January 22, 2013.

Email us at to provide your input or arrange for a phone interview.

For more information about the CDR, the process for submitting input, and for a list of the questions, please click here.